New drug combo trial aims to knock out blood cancer in untreated patients
NCT ID NCT06522386
Summary
This study is testing a combination of three drugs—pirtobrutinib, rituximab, and venetoclax—for adults who have never received treatment for mantle cell lymphoma, a type of blood cancer. The main goal is to see how many patients achieve a complete response, meaning no detectable cancer, and to monitor the safety of this treatment approach. It will enroll about 40 participants to evaluate how well the cancer is controlled and how long the response lasts.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55902, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.